RecruitingCirrhosisLiver Failure
Empagliflozin in Patients With Cirrhosis and Ascites
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
Sponsor: Yale University
You may qualify if…
- ✓ 1. Patients with cirrhosis and ascites on a stable dose of diuretics (spironolactone +/- loop-diuretics based on AASLD guidelines)10 and who do not require large volume paracenteses
- ✓ 2. eGFR \>= 30mL/min/1.73 m2
- ✓ 3. \>=18 years old
You may not qualify if…
- ✕ 1. Hospitalization due to a complication of cirrhosis in the previous 8 weeks (e.g. variceal hemorrhage, encephalopathy, acute kidney injury, spontaneous bacterial peritonitis)
- ✕ 2. Direct bilirubin \>=3 mg/dL
- ✕ 3. Systolic blood pressure \< 100 mmHg
- ✕ 4. Active malignancy including hepatocellular carcinoma undergoing treatment
- ✕ 5. History of bladder dysfunction, incontinence, pyelonephritis, urosepsis, or frequent urinary tract infections
- ✕ 6. Use of SGLT-2 inhibitors in the last 10 days, or previous use with intolerance
- ✕ 7. Type 1 diabetes
- ✕ 8. History of frequent hypoglycemic episodes
Where it's recruiting
Connecticut
New Haven
Source: ClinicalTrials.gov · NCT05726032 · last updated 2026-02-19